
Lantheus Holdings (LNTH) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
372.8M
Gross Profit
237.7M
63.77%
Operating Income
106.8M
28.65%
Net Income
72.9M
19.57%
EPS (Diluted)
$1.02
Balance Sheet Metrics
Total Assets
2.1B
Total Liabilities
891.0M
Shareholders Equity
1.2B
Debt to Equity
0.77
Cash Flow Metrics
Operating Cash Flow
95.5M
Free Cash Flow
98.8M
Revenue & Profitability Trend
Lantheus Holdings Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 1.5B | 1.3B | 935.1M | 425.2M | 339.4M |
Cost of Goods Sold | 545.6M | 586.9M | 353.4M | 237.5M | 200.6M |
Gross Profit | 988.3M | 709.5M | 581.7M | 187.7M | 138.8M |
Gross Margin % | 64.4% | 54.7% | 62.2% | 44.1% | 40.9% |
Operating Expenses | |||||
Research & Development | 168.1M | 77.7M | 311.7M | 45.0M | 32.8M |
Selling, General & Administrative | 371.6M | 267.2M | 233.8M | 218.8M | 110.2M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 539.7M | 344.9M | 545.5M | 263.8M | 143.0M |
Operating Income | 448.6M | 364.6M | 36.2M | -76.1M | -4.2M |
Operating Margin % | 29.2% | 28.1% | 3.9% | -17.9% | -1.2% |
Non-Operating Items | |||||
Interest Income | 36.8M | 19.6M | 2.6M | 45.0K | 238.0K |
Interest Expense | 19.7M | 20.0M | 7.2M | 7.8M | 9.5M |
Other Non-Operating Income | -34.8M | 46.7M | -4.9M | 8.8M | 2.0M |
Pre-tax Income | 431.0M | 410.9M | 26.7M | -75.0M | -11.5M |
Income Tax | 118.5M | 84.3M | -1.3M | -3.8M | 2.0M |
Effective Tax Rate % | 27.5% | 20.5% | -5.0% | 0.0% | 0.0% |
Net Income | 312.4M | 326.7M | 28.1M | -71.3M | -13.5M |
Net Margin % | 20.4% | 25.2% | 3.0% | -16.8% | -4.0% |
Key Metrics | |||||
EBITDA | 551.0M | 444.2M | 86.7M | -33.8M | 20.7M |
EPS (Basic) | $4.52 | $4.79 | $0.41 | $-1.06 | $-0.25 |
EPS (Diluted) | $4.36 | $4.65 | $0.40 | $-1.06 | $-0.25 |
Basic Shares Outstanding | 69199000 | 68266000 | 68487000 | 67486000 | 54134000 |
Diluted Shares Outstanding | 69199000 | 68266000 | 68487000 | 67486000 | 54134000 |
Income Statement Trend
Lantheus Holdings Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 912.8M | 713.7M | 415.7M | 98.5M | 79.6M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 321.3M | 284.3M | 213.4M | 89.3M | 54.0M |
Inventory | 68.0M | 64.0M | 35.5M | 35.1M | 35.7M |
Other Current Assets | 9.1M | 246.0K | 205.0K | 2.7M | 450.0K |
Total Current Assets | 1.3B | 1.1B | 677.6M | 235.8M | 184.2M |
Non-Current Assets | |||||
Property, Plant & Equipment | 36.1M | 45.3M | 19.0M | 8.8M | 18.4M |
Goodwill | 284.1M | 274.4M | 437.7M | 470.9M | 493.3M |
Intangible Assets | 161.8M | 152.0M | 315.3M | 348.5M | 376.0M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 178.4M | 160.1M | 126.0M | 92.7M | 112.3M |
Total Non-Current Assets | 653.7M | 565.3M | 643.6M | 628.0M | 685.6M |
Total Assets | 2.0B | 1.7B | 1.3B | 863.8M | 869.8M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 34.6M | 41.2M | 20.6M | 20.8M | 16.3M |
Short-term Debt | 974.0K | 823.0K | 354.0K | 11.6M | 20.7M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 12.0M | 15.2M | 125.2M | 5.4M | 7.9M |
Total Current Liabilities | 240.5M | 187.4M | 247.7M | 90.5M | 80.5M |
Non-Current Liabilities | |||||
Long-term Debt | 618.5M | 616.1M | 583.2M | 179.7M | 215.2M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 10.0M | 8.9M | 20.7M | 108.3M | 45.9M |
Total Non-Current Liabilities | 651.8M | 647.9M | 626.4M | 308.8M | 275.1M |
Total Liabilities | 892.3M | 835.3M | 874.1M | 399.3M | 355.6M |
Equity | |||||
Common Stock | 709.0K | 699.0K | 689.0K | 677.0K | 669.0K |
Retained Earnings | 445.9M | 133.5M | -193.2M | -221.2M | -149.9M |
Treasury Stock | 175.0M | 75.0M | 75.0M | 0 | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 1.1B | 815.9M | 447.1M | 464.4M | 514.2M |
Key Metrics | |||||
Total Debt | 619.4M | 616.9M | 583.5M | 191.3M | 235.9M |
Working Capital | 1.1B | 898.5M | 429.9M | 145.3M | 103.7M |
Balance Sheet Composition
Lantheus Holdings Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 312.4M | 326.7M | 28.1M | -71.3M | -13.5M |
Depreciation & Amortization | 64.6M | 60.0M | 47.9M | 42.3M | 24.7M |
Stock-Based Compensation | 76.4M | 50.5M | 29.3M | 15.9M | 14.1M |
Working Capital Changes | -44.7M | -90.1M | -138.6M | -31.3M | -18.2M |
Operating Cash Flow | 463.7M | 292.2M | 216.0M | 40.1M | 6.0M |
Investing Activities | |||||
Capital Expenditures | - | - | - | - | - |
Acquisitions | -83.2M | - | 0 | 0 | 17.6M |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | -146.4M | 52.5M | -258.2M | 15.8M | 7.6M |
Financing Activities | |||||
Share Repurchases | -100.0M | 0 | -75.0M | 0 | - |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 0 | 0 | 557.8M | 0 | 0 |
Debt Repayment | -318.0K | -717.0K | -175.4M | -43.3M | -15.5M |
Financing Cash Flow | -121.8M | -16.9M | 304.2M | -44.6M | -21.9M |
Free Cash Flow | 465.1M | 258.7M | 263.4M | 41.8M | 3.9M |
Net Change in Cash | 195.5M | 327.8M | 261.9M | 11.3M | -8.4M |
Cash Flow Trend
Lantheus Holdings Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
14.89
Forward P/E
8.08
Price to Book
3.26
Price to Sales
2.50
PEG Ratio
0.51
Profitability Ratios
Profit Margin
17.82%
Operating Margin
23.27%
Return on Equity
24.71%
Return on Assets
13.34%
Financial Health
Current Ratio
4.29
Debt to Equity
52.75
Beta
0.14
Per Share Data
EPS (TTM)
$3.76
Book Value per Share
$17.16
Revenue per Share
$22.05
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
lnth | 3.8B | 14.89 | 3.26 | 24.71% | 17.82% | 52.75 |
Zoetis | 65.3B | 25.36 | 13.14 | 52.77% | 27.83% | 137.01 |
Haleon Plc - ADR | 43.4B | 21.51 | 5.46 | 9.38% | 13.81% | 53.41 |
Elanco Animal Health | 8.7B | 19.91 | 1.28 | 6.83% | 9.68% | 62.13 |
Regencell Bioscience | 6.1B | - | 878.57 | -47.77% | 0.00% | 0.01 |
Alkermes plc | 4.8B | 14.03 | 2.95 | 23.94% | 23.15% | 4.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.